The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-28 and is reviewed periodically as new material appears.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
=== Resistance === Animals that accumulate TTX as a defense mechanism as well as their predators must evolve to be resistant to the effects of TTX. Mutations in the VGSC genes, especially the genes for Nav 1.4 (skeletal muscle VGSC, "TTX-s"), are found in many such animals. These mutations have independently arisen several times, even multiple times in different populations of the same species as seen in the garter snake. They consist of different amino acid substitutions in similar positions, a weak example of convergent evolution caused by how TTX binds to the unmutated VGSC. Another path to TTX resistance is toxin-binding proteins that hold onto TTX tightly enough to prevent it reaching the vulnerable VGSCs. Various proteins that bind TTX have been found in pufferfish, crabs, and gastropods. There are also proteins that bind saxitoxin (STX), a toxin with a similar mode of action.
=== Use of multi-amino acid scores === While the DIAAS has come to supersede the PDCAAS as the measurement of choice, the original recommendation of the FAO when proposing the DIAAS was that each essential amino acid be treated as a separate nutrient. This would eliminate the need to consider protein content or quality, and would arguably simplify the analysis of the nutrition of meals rather than individual foods. One proposal along these lines is the EAA-9 score, which would measure the percent of RDI of the limiting amino acid of a serving of food. These would be used to determine the EAA-9 Equivalence Serving, or the amount of a food necessary to provide the same amount of that amino acid as an egg.
terms for any measured surfaces. Leighton et al. demonstrated that Gaussian fit data is not accurate for modelling any engineered surfaces and went on to demonstrate that early running of the surfaces results in a gradual transition which significantly changes the surface topography, load carrying capacity and friction. The exact solutions for
Sources: en.wikipedia.org
==== Deuteron mass and radius ==== The deuterium nucleus is called a deuteron. It has a mass of 2.013553212544(15) Da (1875.61294500(58) MeV/c2). The charge radius of a deuteron is 2.12778(27)×10−15 m. Like the proton radius, measurements using muonic deuterium produce a smaller result: 2.12562(78) fm.
== Medication compliance == Medication compliance is defined as the degree to which the patient follows the therapy that is recommended by healthcare professionals. There are direct and indirect methods to evaluate compliance. Direct method refers to the measurement that the healthcare professionals observed or measure the patient's drug-taking behavior. Indirect method refers to the healthcare professionals do not observe or measure the drug-taking behavior of the patient but use the other source of information to evaluate the compliance. The direct method includes measurement of drug (or the corresponding metabolite) concentration, while the indirect method includes pill counting and the self-report from the patient. The direct method is more time-consuming, more expensive, more invasive, but it is more accurate. The indirect method has a lower accuracy but is easier to administer to the patient. If the patient fails to comply with treatment, for example, by not taking the medication according to the instructions, it leads to risk and a poor treatment outcome.
=== Differential diagnosis === Hyperadrenocorticism is a potential differential diagnosis for poor glycaemic control. Hyperadrenocorticism is associated with insulin resistance and is often caused by a pituitary tumour; however, clinical signs differ between the two conditions. Hyperadrenocorticism may cause weight loss, leading to cachexia and alopecia and other dermatological conditions. These symptoms do not show in hypersomatotropism. Diagnostic imaging results for the conditions are often the same, such as hepatomegaly, adrenomegaly, and pituitary mass. Measuring growth hormone and IGF-1 levels can differentiate the diseases when physical symptoms are unremarkable. Dogs with primary hypothyroidism also have increased levels of growth hormone and IGF-1; however, thyroxine and thyroid stimulating hormone levels are normal in dogs with hypersomatotropism. Progestogens administered to dogs may result in endogenous adrenocorticotropic hormone secretion being suppressed, which lowers the cortisol concentration.
Sources: en.wikipedia.org
== Opposition to atomic theory == Dalton's atomic theory attracted widespread interest but not universal acceptance. One problem was the lack of uniform nomenclature. The word "atom" implied indivisibility, but Dalton defined an atom as being the ultimate particle of any chemical substance, not just the elements or even matter per se. This meant that "compound atoms" such as carbon dioxide could be divided, as opposed to "elementary atoms". Dalton disliked the word "molecule", regarding it as "diminutive". Amedeo Avogadro did the opposite: he exclusively used the word "molecule" in his writings, eschewing the word "atom", instead using the term "elementary molecule". Jöns Jacob Berzelius used the term "organic atoms" to refer to particles containing three or more elements, because he thought this only existed in organic compounds. Jean-Baptiste Dumas used the terms "physical atoms" and "chemical atoms"; a "physical atom" was a particle that cannot be divided by physical means such as temperature and pressure, and a "chemical atom" was a particle that could not be divided by chemical reactions. The modern definitions of atom and molecule—an atom being the basic particle of an element, and a molecule being an agglomeration of atoms—were established in the latter half of the 19th century. A key event was the Karlsruhe Congress in Germany in 1860. As the first international congress of chemists, its goal was to establish some standards in the community. A major proponent of the modern distinction between atoms and molecules was Stanislao Cannizzaro.
A point mutation is a genetic mutation where a single nucleotide base is changed, inserted or deleted from a DNA or RNA sequence of an organism's genome. Point mutations have a variety of effects on the downstream protein product—consequences that are moderately predictable based upon the specifics of the mutation. These consequences can range from no effect (e.g. synonymous mutations) to deleterious effects (e.g. frameshift mutations), with regard to protein production, composition, and function.
Engines (includes all models from 1998 to 2003) 1.3 L B3-ME SOHC I4 1.5 L ZL-DE DOHC I4 1.5 L ZL-VE S-VT I4 1.6 L ZM-DE DOHC I4 1.8 L FP-DE DOHC I4 2.0 L FS, 130 hp (97 kW; 132 PS) / 135 lb⋅ft (183 N⋅m) 2.0 L FS-ZE (2001 Sport 20) 2.0 L RF Diesel
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.